Veraxa Biotech Holding AG (VRXA) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4

Key dataNov 4, 2026

Open$0.99

From 52W high−96.01%

Volume60016.00

Market cap$139.99M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataNov 4, 2026

Open

$0.99

From 52W high

−96.01%

Volume

60016.00

Market cap

$139.99M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

—

P/E (TTM)

—

RSI (14)

39.4

MomentumView details →

1D Return

+0.00%

YTD Return

—

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

—

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

—

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

—

ROA (TTM)

—

Asset Turnover

—

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

—

EBITDA YoY

—

MomentumView details →

1D Return

+0.00%

YTD Return

—

1Y Return

—

RSI (14)

39.4

vs 50D SMA

−22.62%

vs 200D SMA

—

Capital & dividendView details →

Debt/Equity

—

Current Ratio

—

Quick Ratio

—

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

—

EPS Surprise

—

Beats (12Q)

—

Next Q EPS Est

—

Avg Surprise (4Q)

—

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

—

Net Income (TTM)

—

Op. CF (TTM)

—

Latest newsMore news →

Veraxa Biotech Holding AG presented first in vivo proof-of-concept data for its BiTAC®-ADC technology at the World ADC Congress, showing tumor-selective activation, potent anti-tumor efficacy and improved safety.22d ago

VERAXA Biotech is shifting focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products after completing its business combination and starting Nasdaq trading in June 2026.41d ago

Similar companies

Compass Therapeutics, Inc.CMPX Protara Therapeutics, Inc.TARA Cue Biopharma, Inc.CUE NervGen Pharma Corp. Common stockNGEN MacroGenics, Inc.MGNX Coherus Oncology, Inc.CHRS Find similar companies →

Latest newsMore news →

Veraxa Biotech Holding AG presented first in vivo proof-of-concept data for its BiTAC®-ADC technology at the World ADC Congress, showing tumor-selective activation, potent anti-tumor efficacy and improved safety.22d ago VERAXA Biotech is shifting focus to advancing its oncology pipeline and implementing industrial partnerships for its technology platforms and products after completing its business combination and starting Nasdaq trading in June 2026.41d ago VERAXA Biotech announced a collaboration with Ardigen to support its BiTAC pipeline of T cell engagers and antibody drug conjugates.114d ago